Recent research has shown that certain forms of E. coli bacteria tend to colonize hypoxic areas of the body, including tumors, suggesting they might be playing a role in cancer therapeutics. A team of researchers at Dana-Farber Cancer Institute led by Dr. Romee in collaboration with Dr. Jiahe Li at the University of Michigan engineered gut derived E. coli bacteria to express immune-activating cytokines on their surfaces, with the idea that the bacteria would move into the tumor and induce potent immune responses.
This is an automated archive made by the Lemmit Bot.